118 related articles for article (PubMed ID: 37726192)
1. Control of diabetes mellitus and the risk of neointimal hyperplasia after percutaneous coronary intervention: Post-hoc analysis from the BLADE-PCI trial.
Jonas M; Genereux P; Maehara A; Ben-Yehuda O; Stone GW; Chernin G
Atherosclerosis; 2024 Jul; 394():117264. PubMed ID: 37726192
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus: The RESERVOIR Clinical Trial.
Romaguera R; Gómez-Hospital JA; Gomez-Lara J; Brugaletta S; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Montanya E; Fernandez-Ortiz A; Alfonso F; Valgimigli M; Sabate M; Cequier A
JACC Cardiovasc Interv; 2016 Jan; 9(1):42-50. PubMed ID: 26762910
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Early Healing Profile and Neointimal Transformation Over 24 Months Using Longitudinal Sequential Optical Coherence Tomography Assessments and 3-Year Clinical Results of the New Dual-Therapy Endothelial Progenitor Cell Capturing Sirolimus-Eluting Combo Stent: The EGO-Combo Study.
Lee SW; Lam SC; Tam FC; Chan KK; Shea CP; Kong SL; Wong AY; Yung A; Zhang LW; Tse HF; Wu KK; Chan R; Haude M; Mehran R; Mintz GS; Maehara A
Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27418609
[TBL] [Abstract][Full Text] [Related]
4. A prospective, multicenter, randomized OCT study of early neointimal condition at first and second months after BuMA Supreme stent versus XIENCE stent implantation in high-bleeding-risk coronary artery disease patients: study protocol for a randomized controlled trial.
Li B; Jin QH; Chen YD; Wang CQ; Shi B; Su X; Fu GS; Wu YQ; Zhou XC; Yuan ZY
Trials; 2019 Jun; 20(1):335. PubMed ID: 31174600
[TBL] [Abstract][Full Text] [Related]
5. The OCT-ORION Study: A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-Eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.
Lee SWL; Tam FCC; Lam SCC; Kong SL; Shea CP; Chan KKW; Wong MKL; Chan MPH; Wong AYT; Yung ASY; Lam YM; Zhang LW; Wu KKY; Mintz GS; Maehara A
Circ Cardiovasc Interv; 2018 Apr; 11(4):e006034. PubMed ID: 29654119
[TBL] [Abstract][Full Text] [Related]
6. Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.
Puri R; Otaegui I; Sabaté M; Serra-Peñaranda A; Puigfel M; Perez de Prado A; Nombela-Franco L; de la Torre Hernandez JM; Ortas Nadal R; Iniguez-Romo A; Jiménez G; Fernandez-Vazquez F; Cuellas-Ramon C; Gonzalo N; Alfonso Jiménez Diaz V; Duocastella L; Molina M; Amoros M; Perez I; Barria Perez A; Pelletier Beaumont E; Nicholls SJ; Garcia Del Blanco B; Rodés-Cabau J
Catheter Cardiovasc Interv; 2018 Feb; 91(3):435-443. PubMed ID: 28707379
[TBL] [Abstract][Full Text] [Related]
7. Intimal hyperplasia and vascular remodeling after everolimus-eluting and sirolimus-eluting stent implantation in diabetic patients: the randomized Diabetes and Drug-Eluting Stent (DiabeDES) IV Intravascular Ultrasound trial.
Antonsen L; Maeng M; Thayssen P; Christiansen EH; Hansen KN; Kaltoft A; Hansen HS; Thuesen L; Lassen JF; Jensen LO
Catheter Cardiovasc Interv; 2014 May; 83(6):864-72. PubMed ID: 23996918
[TBL] [Abstract][Full Text] [Related]
8. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
Sakata K; Waseda K; Kume T; Otake H; Nakatani D; Yock PG; Fitzgerald PJ; Honda Y
Circ Cardiovasc Interv; 2012 Dec; 5(6):763-71. PubMed ID: 23149332
[TBL] [Abstract][Full Text] [Related]
9. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
[TBL] [Abstract][Full Text] [Related]
10. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
[TBL] [Abstract][Full Text] [Related]
11. Neointimal coverage of zotarolimus-eluting stent at 1, 2, and 3 months' follow-up: an optical coherence tomography study.
Hashikata T; Tojo T; Namba S; Kitasato L; Hashimoto T; Kameda R; Shimohama T; Yamaoka-Tojo M; Ako J
Heart Vessels; 2016 Feb; 31(2):206-11. PubMed ID: 25362579
[TBL] [Abstract][Full Text] [Related]
12. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
[TBL] [Abstract][Full Text] [Related]
13. Serial Assessment of Strut Coverage of Biodegradable Polymer Drug-Eluting Stent at 1, 2, and 3 Months After Stent Implantation by Optical Frequency Domain Imaging: The DISCOVERY 1TO3 Study (Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent With Biodegradable Polymer at 1, 2, and 3 Months).
Chevalier B; Smits PC; Carrié D; Mehilli J; Van Boven AJ; Regar E; Sawaya FJ; Chamié D; Kraaijeveld AO; Hovasse T; Vlachojannis GJ
Circ Cardiovasc Interv; 2017 Dec; 10(12):. PubMed ID: 29246909
[TBL] [Abstract][Full Text] [Related]
14. Comparison Between Optical Frequency Domain Imaging and Intravascular Ultrasound for Percutaneous Coronary Intervention Guidance in Biolimus A9-Eluting Stent Implantation: A Randomized MISTIC-1 Non-Inferiority Trial.
Muramatsu T; Ozaki Y; Nanasato M; Ishikawa M; Nagasaka R; Ohota M; Hashimoto Y; Yoshiki Y; Takatsu H; Ito K; Kamiya H; Yoshida Y; Murohara T; Izawa H;
Circ Cardiovasc Interv; 2020 Nov; 13(11):e009314. PubMed ID: 33106049
[TBL] [Abstract][Full Text] [Related]
15. First-in-man study evaluating the safety and efficacy of a second generation biodegradable polymer sirolimus-eluting stent in the treatment of patients with de novo coronary lesions: clinical, Angiographic, and OCT outcomes of CREDIT-1.
Wang G; Sun Z; Jin Q; Xu K; Li Y; Wang X; Ma Y; Liu H; Zhao X; Wang B; Deng J; Guan S; Ge M; Wang X; Xu B; Han Y
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():744-51. PubMed ID: 25630447
[TBL] [Abstract][Full Text] [Related]
16. Optical coherence tomographic comparison of neointimal coverage between sirolimus- and resolute zotarolimus-eluting stents at 9 months after stent implantation.
Kim JS; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
Int J Cardiovasc Imaging; 2012 Aug; 28(6):1281-7. PubMed ID: 21858655
[TBL] [Abstract][Full Text] [Related]
17. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes.
Hashikata T; Ikutomi M; Jimba T; Shindo A; Kakuda N; Katsushika S; Yokoyama M; Kishi M; Sato T; Matsushita M; Ohnishi S; Yamasaki M
Heart Vessels; 2020 Oct; 35(10):1378-1389. PubMed ID: 32399662
[TBL] [Abstract][Full Text] [Related]
19. Randomized Angiographic and Intravascular Ultrasound Comparison of Dual-Antiplatelet Therapy vs Triple-Antiplatelet Therapy to Reduce Neointimal Tissue Proliferation in Diabetic Patients.
Zuliani Mauro MF; Mangione JA; Costa JR; Costa R; Piva E Mattos LA; Staico R; Feres F; Siqueira D; Sousa A; Abizaid A
J Invasive Cardiol; 2017 Mar; 29(3):76-81. PubMed ID: 28255102
[TBL] [Abstract][Full Text] [Related]
20. Comparison of neointimal hyperplasia and peri-stent vascular remodeling after implantation of everolimus-eluting versus sirolimus-eluting stents: intravascular ultrasound results from the EXCELLENT study.
Ko YG; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Gwon HC; Ahn T; Chae IH; Yoon JH; Kim HS; Jang Y;
Int J Cardiovasc Imaging; 2013 Aug; 29(6):1229-36. PubMed ID: 23456359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
